Authors: Sharon Salt, Editor
In this week’s industry news round-up we cover the latest headlines on the clearance of gammaCore™ for cluster headache, warnings of stroke risk with a multiple sclerosis drug and an investigational gene therapy for spinal muscular atrophy. Find out more about our selection of the highlights below.
Our selection of the highlights includes:
gammaCore™ receives clearance for the preventive treatment of cluster headache
electroCore (NJ, USA) has announced that it has received clearance from the US FDA for an expanded label for gammaCore™ therapy, a non-invasive vagus nerve stimulator (nVNS), for the adjunctive use for the preventive treatment of cluster headache in adult patients.